Hill A V, Elvin J, Willis A C, Aidoo M, Allsopp C E, Gotch F M, Gao X M, Takiguchi M, Greenwood B M, Townsend A R
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK.
Nature. 1992 Dec 3;360(6403):434-9. doi: 10.1038/360434a0.
The protective association between the human leukocyte antigen HLA-B53 and severe malaria was investigated by sequencing of peptides eluted from this molecule followed by screening of candidate epitopes from pre-erythrocytic-stage antigens of Plasmodium falciparum in biochemical and cellular assays. Among malaria-immune Africans, HLA-B53-restricted cytotoxic T lymphocytes recognized a conserved nonamer peptide from liver-stage-specific antigen-1 (LSA-1), but no HLA-B53-restricted epitopes were identified in other antigens. These findings indicate a possible molecular basis for this HLA-disease association and support the candidacy of liver-stage-specific antigen-1 as a malaria vaccine component.
通过对从该分子洗脱的肽段进行测序，随后在生化和细胞试验中筛选恶性疟原虫红细胞前期抗原的候选表位，研究了人类白细胞抗原HLA - B53与严重疟疾之间的保护性关联。在对疟疾具有免疫力的非洲人中，HLA - B53限制性细胞毒性T淋巴细胞识别出一种来自肝期特异性抗原-1（LSA - 1）的保守九肽，但在其他抗原中未鉴定出HLA - B53限制性表位。这些发现表明了这种HLA与疾病关联的可能分子基础，并支持肝期特异性抗原-1作为疟疾疫苗成分的候选资格。
